Brokerages Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Target Price at $19.00

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has been assigned an average recommendation of “Moderate Buy” from the ten ratings firms that are covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $19.00.

A number of analysts have recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research report on Tuesday, April 21st. Leerink Partners reissued an “outperform” rating on shares of Fulcrum Therapeutics in a research report on Tuesday, February 24th. Wall Street Zen raised Fulcrum Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 2nd. Finally, Truist Financial set a $17.00 price objective on Fulcrum Therapeutics in a research report on Tuesday, February 24th.

Institutional Trading of Fulcrum Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Aberdeen Group plc lifted its position in Fulcrum Therapeutics by 135.0% during the 3rd quarter. Aberdeen Group plc now owns 137,961 shares of the company’s stock worth $1,269,000 after acquiring an additional 79,265 shares during the period. Braidwell LP acquired a new stake in Fulcrum Therapeutics during the 3rd quarter worth about $2,019,000. Boothbay Fund Management LLC lifted its position in Fulcrum Therapeutics by 104.2% during the 3rd quarter. Boothbay Fund Management LLC now owns 678,414 shares of the company’s stock worth $6,241,000 after acquiring an additional 346,136 shares during the period. Suvretta Capital Management LLC lifted its position in Fulcrum Therapeutics by 5.9% during the 3rd quarter. Suvretta Capital Management LLC now owns 5,381,000 shares of the company’s stock worth $49,505,000 after acquiring an additional 298,100 shares during the period. Finally, GSA Capital Partners LLP lifted its position in Fulcrum Therapeutics by 256.4% during the 3rd quarter. GSA Capital Partners LLP now owns 116,068 shares of the company’s stock worth $1,068,000 after acquiring an additional 83,505 shares during the period. Institutional investors and hedge funds own 89.83% of the company’s stock.

Fulcrum Therapeutics Price Performance

Fulcrum Therapeutics stock opened at $6.92 on Friday. The stock has a market capitalization of $461.08 million, a price-to-earnings ratio of -6.02 and a beta of 3.02. Fulcrum Therapeutics has a 1-year low of $5.88 and a 1-year high of $15.74. The business has a fifty day moving average price of $7.24 and a 200-day moving average price of $9.22.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings data on Monday, April 27th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.06. On average, equities research analysts anticipate that Fulcrum Therapeutics will post -1.16 earnings per share for the current fiscal year.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small?molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.